Close Menu
June 03, 2019

A Non-Small Cell Lung Cancer Reference Material

Partner Webinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

About 10-50 percent of Non-small-cell lung cancers have one of several activating EGFR driver mutations that have been clinically validated as therapeutic biomarkers for anti-EGFR drugs. Identifying these driver mutations through liquid biopsies is a promising alternative to traditional biopsies; however, the precision of mutation analysis for some of these targets remains a challenge.